The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae

Journal of Infection and Chemotherapy

Volumn 9, Issue 3, 2003, Pages 210-214

  Ebisu, Hiroyuki ^a   Kishii, Ryuta ^a   Takei, Masaya ^a   Fukuda, Hideyuki ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

AUC24h MIC; Cmax MIC; Gatifloxacin; In vitro pharmacokinetic model; Streptococcus pneumoniae

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ERADICATION THERAPY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN IDENTIFICATION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0142026524     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-003-0243-9     Document Type: Article

References (19)

1. Tsurumaki Y, Manda H, Takei M, Hosaka M. In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan. J Antimicrob Chemother 2000;45:685-9.
2. Doerm GV, Pfaller MA, Kugler K, Freeman J, Joes RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998;27:764-70.
3. Hosaka M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K. In vitro and in vivo antibacterial activity of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992;36:2108-17.
4. Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1994;38:594-601.
5. Lister PD. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Antimicrob Agents Chemother 2002;46:69-74.
6. Lacey MK, Xiaowei WL, Tessier PR, Nicolau DP, Quintilliani R, Nightngale CH. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999;43:672-7.
7. Lister PD, Sanders CC. Pharmacodynamics of trovafloxacin, ofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1999;43:1118-23.
8. Hershberger E, Rybak MJ. Activities of trovafloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother 2000;44:598-601.
9. Zhanel GG, Roberts D, Waltky A, Laing N, Nichol K, Hoban DJ. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2002;49:807-12.
10. Madaras-Kelly KJ, Demasters TA. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000;37:253-60.
11. Thorburn CE, Edwards D. The effect of pharmacokinetics on the bactericidal activity of ciprolloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. J Antimicrob Chemother 2001;48:15-22.
12. Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 2001;45:673-8.
13. Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Uchida H. Phase I study of gatifloxacin, a new quinolone I.Single-dose study. Jpn J Chemotherapy 1999;47(S-2):175-207.
14. Nakajima M, Uematsu T, Kanamaru M, Okazai O, Hakusui H. Phase I study of levofloxacin, (S)-(-)-ofloxacin. Jpn J Clin Pharmacol Ther 1992;23:515-20.
15. Matsumoto F, Kobayashi H, Takamura K, Takeda H. Pharmacokinetics with BAY O 9867 (ciprofloxacin). Jpn J Chemotherapy 1985;33(S-7):140-88.
16. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:410-12.
17. Fukuda H. Genetic study of the mechanism of fluoroquinolones in Streptococcus pneumoniae. Jpn J Chemother 2000;48:243-50.
18. Fukuda H, Kishii R, Takei M, Hosaka M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference and antibacterial activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:1649-53.
19. Madaras-Kelly KJ, Ostergaad BE, Hovde LB, Rotscafer JC. Twenty-four-hour area the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996;40:627-32.